AstraZeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. Established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the United Kingdom, the company focuses on the discovery, development, manufacture and commercialization of prescription medicines. Its research and development efforts center on four main therapy areas: oncology; cardiovascular, renal and metabolism; respiratory and immunology; and biopharmaceuticals such as vaccines.

The company’s product portfolio includes a range of treatments for cancer, heart and kidney diseases, diabetes, asthma and chronic obstructive pulmonary disease. Central to its strategy is investment in innovative science and partnerships with biotechnology firms, academic institutions and healthcare organizations. Notable products include targeted oncology therapies that inhibit tumor growth pathways, as well as inhaled and biologic treatments designed to modulate the immune response in respiratory disorders.

AstraZeneca operates in over 100 countries, with major research sites and manufacturing facilities across Europe, North America, Asia and emerging markets in Latin America, the Middle East and Africa. This geographic footprint supports global clinical trials, regulatory filings and market launches while enabling the company to address diverse patient needs and health care systems. AstraZeneca also collaborates with public health agencies and nonprofit organizations on initiatives ranging from vaccine deployment to access programs in underserved regions.

Since 2012, Pascal Soriot has served as Chief Executive Officer, guiding the company through a period of significant pipeline expansion and commercial growth. Under his leadership, AstraZeneca has secured key approvals for breakthrough therapies and has reinforced its commitment to sustainability, ethical business practices and patient-centric innovation. The company continues to pursue long-term value creation through a balanced mix of internal research, external partnerships and disciplined portfolio management.

Key Stats

• Today's Range: $79.43 to $80.59
• 50-Day Range: $68.72 to $80.97
• 52-Week Range: $61.24 to $87.25
• Volume: 1.97 million shs
• Average Volume: 5.20 million shs
• Market Capitalization: $248.05 billion
• P/E Ratio: 30.05
• Dividend Yield: 1.26%
• Price Target: $86.00
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 47% of companies evaluated by MarketBeat, and ranked 460th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

AstraZeneca has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.86%

Earnings Growth

Earnings for AstraZeneca are expected to grow by 10.86% in the coming year, from $4.51 to $5.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 30.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.24.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 30.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.63.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 1.47. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the outstanding shares of AstraZeneca have been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently increased by 16.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

AstraZeneca pays a meaningful dividend of 1.26%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.20% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.20% of the outstanding shares of AstraZeneca have been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently increased by 16.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.43

News Sentiment

AstraZeneca has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.13 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for AstraZeneca this week, compared to 23 articles on an average week.

Search Interest

Only 24 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

MarketBeat Follows

11 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 20.35% of the stock of AstraZeneca is held by institutions.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?

AstraZeneca's stock was trading at $65.52 on January 1st, 2025. Since then, AZN shares have increased by 22.1% and is now trading at $79.98.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) issued its quarterly earnings results on Tuesday, July, 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. The company's quarterly revenue was up 16.1% compared to the same quarter last year.
Read the conference call transcript.

When did AstraZeneca's stock split?

AstraZeneca's stock split before market open on Monday, July 27th 2015.The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does AstraZeneca have any subsidiaries?

AstraZeneca subsidiaries include these companies: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and more.

Who are AstraZeneca's major shareholders?

AstraZeneca's top institutional shareholders include Primecap Management Co. CA (1.33%), Bank of America Corp DE (1.01%), Franklin Resources Inc. (0.69%) and Fisher Asset Management LLC (0.67%).
View institutional ownership trends.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/29/2025
• Record date for 9/8 Dividend: 8/08/2025
• Ex-Dividend for 9/8 Dividend: 8/08/2025
• Today: 9/02/2025
• Dividend Payable: 9/08/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AZN
• CIK: 901832
• Web: www.astrazeneca.com
• Phone: 442037495000
• Fax: 44-12-2335-2858
• Employees: 94,300
• Year Founded: 1999

Price Target and Rating

• Average Price Target for AstraZeneca: $86.00
• High Price Target: $97.00
• Low Price Target: $75.00
• Potential Upside/Downside: +7.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.66
• Trailing P/E Ratio: 30.02
• Forward P/E Ratio: 17.70
• P/E Growth: 1.47
• Net Income: $7.04 billion
• Net Margins: 14.68%
• Pretax Margin: 17.74%
• Return on Equity: 32.84%
• Return on Assets: 12.87%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 0.86
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $54.07 billion
• Price / Sales: 4.58
• Cash Flow: $6.29 per share
• Price / Cash Flow: 12.69
• Book Value: $13.18 per share
• Price / Book: 6.06

Miscellaneous

• Outstanding Shares: 3,101,360,000
• Free Float: N/A
• Market Cap: $247.61 billion
• Optionable: Optionable
• Beta: 0.37